Sutro Biopharma, Inc. (STRO): Total Assets
$173.83M
As of 2025-12-31
$194.46M
As of 2026-06-30
-24.7%
3-year compound annual growth
-15.1%
5-year compound annual growth
| Period ended | Total Assets | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $173.83M | -55.1% | 2026-03-23, Balance as of period end |
| 2024-12-31 | $387.21M | -17.7% | 2026-03-23, Balance as of period end |
| 2023-12-31 | $470.74M | +15.7% | 2025-03-13, Balance as of period end |
| 2022-12-31 | $406.94M | +19.2% | 2024-03-25, Balance as of period end |
| 2021-12-31 | $341.41M | -13.4% | 2023-03-30, Balance as of period end |
| 2020-12-31 | $394.11M | +152.0% | 2022-02-28, Balance as of period end |
| 2019-12-31 | $156.37M | -29.9% | 2021-03-18, Balance as of period end |
| 2018-12-31 | $223.14M | +447.3% | 2020-03-16, Balance as of period end |
| 2017-12-31 | $40.77M | n/a | 2019-04-01, Balance as of period end |
Total Assets at similar companies
| Company | Year ended | Total Assets | Change YoY |
|---|---|---|---|
| Sutro Biopharma, Inc. (STRO) | 2025-12-31 | $173.83M | -55.1% |
| Century Therapeutics, Inc. (IPSC) | 2025-12-31 | $223.70M | -36.7% |
| ImmunityBio, Inc. (IBRX) | 2025-12-31 | $501.90M | +31.1% |
| Agenus Inc (AGEN) | 2025-12-31 | $226.80M | +0.2% |
| Atara Biotherapeutics, Inc. (ATRA) | 2025-12-31 | $20.23M | -81.5% |
| 4D Molecular Therapeutics, Inc. (FDMT) | 2025-12-31 | $566.71M | +1.1% |
| Monte Rosa Therapeutics, Inc. (GLUE) | 2025-12-31 | $448.66M | +2.3% |
| MeiraGTx Holdings plc (MGTX) | 2025-12-31 | $244.43M | -9.4% |
| Autolus Therapeutics plc (AUTL) | 2025-12-31 | $589.07M | -24.7% |
Compare STRO, IPSC, IBRX, AGEN side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗